Drug Chatter -- Tracking biopharma stock chatter

DrugPatentWatch - Biopharmaceutical Business Intelligence

Profile for Lifevantage Corporation (LXRX)

« Back to company index

LXRX Chatter Timeline

Stock Ticker for LXRX

Most Active Tweeters for LXRX

UserTweets
@gcassidy718 5
@AmericanBanking 4
@dispatchtribune 3
@BlueBioNow 3
@ZolmaxNews 3

Recent Tweets for LXRX

AmericanBanking @AmericanBanking
Investment Analysts’ Weekly Ratings Changes for Lexicon Pharmaceuticals $LXRX https://t.co/1eKRitdAtd #stocks
April 1st 2020, 8:04pm
gcassidy718 @gcassidy718
$LXRX This one is getting bipolar : ) 3.99 % change recently https://t.co/GvztssB0iO
March 31st 2020, 3:03pm
BlueBioNow @BlueBioNow
$LXRX buyer at $1.98 -7.69 % change recently https://t.co/e90khvbZCK
March 31st 2020, 2:03am
gcassidy718 @gcassidy718
$LXRX Do we see $2.06 next?  3.89 % change recently https://t.co/GvztssB0iO
March 30th 2020, 7:03pm
dailypoliticaln @dailypoliticaln
Lexicon Pharmaceuticals $LXRX Stock Price Down 7.7% https://t.co/rRSah1PDiB
March 29th 2020, 6:03am
BlueBioNow @BlueBioNow
$LXRX major moves #LXRX -3.08 % change recently https://t.co/e90khvbZCK
March 27th 2020, 8:03pm
HealthcareBeat @HealthcareBeat
Lexicon Pharmaceuticals’ Buy Rating Reaffirmed at Wedbush $LXRX https://t.co/D7QRgUR8M9
March 27th 2020, 4:03am
dakotafinancial @dakotafinancial
Lexicon Pharmaceuticals’ $LXRX Buy Rating Reaffirmed at Wedbush https://t.co/KcUO12oPjP
March 27th 2020, 4:03am
stocknewstimes @stocknewstimes
Lexicon Pharmaceuticals’ $LXRX Buy Rating Reaffirmed at Wedbush https://t.co/ySBoSfGT67
March 27th 2020, 4:03am
gcassidy718 @gcassidy718
$LXRX I am gona keep buying until it hits $2.06 dollars -2.09 % change https://t.co/GvztssB0iO
March 26th 2020, 11:03am
ConsumerFeed @ConsumerFeed
Wedbush Reaffirms Buy Rating for Lexicon Pharmaceuticals $LXRX https://t.co/1ISHB12WvY
March 26th 2020, 3:03am
ZolmaxNews @ZolmaxNews
Wedbush Reaffirms Buy Rating for Lexicon Pharmaceuticals $LXRX https://t.co/yNOkTQysHJ
March 26th 2020, 3:03am
TranscriptDaily @TranscriptDaily
Wedbush Reaffirms Buy Rating for Lexicon Pharmaceuticals $LXRX https://t.co/ruKzKLw6PD
March 26th 2020, 3:03am
dailypoliticaln @dailypoliticaln
Wedbush Reaffirms Buy Rating for Lexicon Pharmaceuticals $LXRX https://t.co/yC0uSKWbvF
March 26th 2020, 3:03am
jomariexx @jomariexx
@pawcio2009 $LXRX waaaay more frustrating
March 25th 2020, 5:03pm
BlueBioNow @BlueBioNow
$LXRX that looks like an 'I can't believe I gave you so much money and you're blowing it' kinda hand strangle -2.2… https://t.co/9NsYrUwEYE
March 25th 2020, 4:03pm
TheMarketsDaily @TheMarketsDaily
Lexicon Pharmaceuticals $LXRX Rating Reiterated by Wedbush https://t.co/geDcPaBWqP
March 25th 2020, 5:03am
TickerReport @TickerReport
Lexicon Pharmaceuticals $LXRX Rating Reiterated by Wedbush https://t.co/JhZYCA4Sd6
March 25th 2020, 5:03am
dispatchtribune @dispatchtribune
Lexicon Pharmaceuticals $LXRX Rating Reiterated by Wedbush https://t.co/V2K852LR7a
March 25th 2020, 5:03am
AmericanBanking @AmericanBanking
Lexicon Pharmaceuticals $LXRX Stock Rating Reaffirmed by Wedbush https://t.co/drWQgEbNfk #stocks
March 24th 2020, 10:03pm
SeekingAlpha @SeekingAlpha
$LXRX - Lexicon Pharmaceuticals Moving On From Diabetes And Pivoting Toward Clinical Candidates.… https://t.co/GWtm260f98
March 24th 2020, 5:03pm
WatchlistN @WatchlistN
Zacks: Analysts Expect Lexicon Pharmaceuticals, Inc. $LXRX Will Announce Earnings of -$0.66 Per Share https://t.co/EZfEYr4TVV
March 23rd 2020, 9:03am
dispatchtribune @dispatchtribune
Lexicon Pharmaceuticals, Inc. $LXRX Expected to Announce Earnings of -$0.66 Per Share https://t.co/IsBUvyk3Fl
March 23rd 2020, 9:03am
ZolmaxNews @ZolmaxNews
Lexicon Pharmaceuticals, Inc. $LXRX Expected to Announce Earnings of -$0.66 Per Share https://t.co/BZSurL0BVe
March 23rd 2020, 9:03am
TheMarketsDaily @TheMarketsDaily
Lexicon Pharmaceuticals, Inc. $LXRX Expected to Announce Earnings of -$0.66 Per Share https://t.co/ONQD6MK9nz
March 23rd 2020, 9:03am
gcassidy718 @gcassidy718
$LXRX Never should have bought this stock . . . -14.83 % change recently https://t.co/GvztssB0iO
March 23rd 2020, 5:03am
HealthcareBeat @HealthcareBeat
LEXICON PHARMACEUTICALS PROVIDES AN UPDATE ON THE SOTAGLIFLOZIN TYPE 2 DIABETES PROGRAM $LXRX https://t.co/RB7hM48HPh
March 23rd 2020, 1:03am
HealthcareBeat @HealthcareBeat
Lexicon shuts down two Zynquista studies due to funding issues $LXRX https://t.co/Gj0bcLkRPH
March 22nd 2020, 11:03pm
ConsumerFeed @ConsumerFeed
Lexicon Pharmaceuticals $LXRX Trading Down 15.9% https://t.co/62ly2FEF37
March 22nd 2020, 8:03am
TickerReport @TickerReport
Lexicon Pharmaceuticals, Inc. $LXRX Expected to Announce Quarterly Sales of $7.07 Million https://t.co/wwCVansntt
March 22nd 2020, 4:03am
AmericanBanking @AmericanBanking
Lexicon Pharmaceuticals, Inc. $LXRX Expected to Announce Quarterly Sales of $7.07 Million https://t.co/p65txiLvT5 #stocks
March 22nd 2020, 4:03am
stocknewstimes @stocknewstimes
Lexicon Pharmaceuticals, Inc. $LXRX Receives $7.00 Average Target Price from Brokerages https://t.co/3Y59ei2PX8
March 21st 2020, 12:03pm
gcassidy718 @gcassidy718
$LXRX Looking for any entry here......... ;) 2.66 % change recently https://t.co/GvztssB0iO
March 20th 2020, 8:03am
OpenOutcrier @OpenOutcrier
$LXRX (-10.6% pre) LEXICON PHARMACEUTICALS PROVIDES AN UPDATE ON THE SOTAGLIFLOZIN TYPE 2 DIABETES PROGRAM https://t.co/FQvF2HuVnu
March 20th 2020, 8:03am
TickerReport @TickerReport
Zacks: Brokerages Anticipate Lexicon Pharmaceuticals, Inc. $LXRX Will Announce Earnings of -$0.66 Per Share https://t.co/BUWNjWdSGp
March 20th 2020, 4:03am
AmericanBanking @AmericanBanking
Zacks: Brokerages Anticipate Lexicon Pharmaceuticals, Inc. $LXRX Will Announce Earnings of -$0.66 Per Share https://t.co/q6DE52xyx3 #stocks
March 20th 2020, 4:03am
ThisLincolnian @ThisLincolnian
-$0.66 EPS Expected for Lexicon Pharmaceuticals, Inc. $LXRX This Quarter https://t.co/wlvA8R7fVn
March 20th 2020, 4:03am
ZolmaxNews @ZolmaxNews
Research Analysts Set Expectations for Lexicon Pharmaceuticals, Inc.’s Q1 2021 Earnings $LXRX https://t.co/c8PQViZWCt
March 20th 2020, 3:03am
dispatchtribune @dispatchtribune
Lexicon Pharmaceuticals, Inc. $LXRX Forecasted to Earn Q1 2021 Earnings of -$0.35 Per Share https://t.co/fIBbMpWGBh
March 20th 2020, 3:03am
Briefingcom @Briefingcom
$LXRX: Lexicon Pharma provides update for Zynquista program in type 2 diabetes; to close out SCORED and SOLOIST... https://t.co/rTrbAzTXP0
March 19th 2020, 6:03pm
Gambiste1 @Gambiste1
RT @MaisaCorp: $LXRX will close out early its two long-term outcomes studies of sotagliflozin, Scored and Soloist, for heart failure and ch…
March 19th 2020, 5:03pm
MaisaCorp @MaisaCorp
$LXRX will close out early its two long-term outcomes studies of sotagliflozin, Scored and Soloist, for heart failu… https://t.co/XaP6Nq5sXD
March 19th 2020, 5:03pm
StckPro @StckPro
$LXRX NEW ARTICLE : Lexicon shuts down two Zynquista studies due to funding issues https://t.co/FDwbEnzyhD Get all… https://t.co/2Y8sEqSZIB
March 19th 2020, 4:03pm
otcdynamics @otcdynamics
$LXRX LEXICON PHARMACEUTICALS PROVIDES AN UPDATE ON THE SOTAGLIFLOZIN TYPE 2 DIABETES PROGRAM https://t.co/BLfFe3CQAu
March 19th 2020, 4:03pm
MarketCurrents @MarketCurrents
$LXRX - Lexicon shuts down two Zynquista studies due to funding issues https://t.co/laoE3SQIWO
March 19th 2020, 4:03pm
Kevin_W81 @Kevin_W81
$LXRX Ends ZynquistaTM (sotagliflozin) program in type 2 diabetes "near-term partnership sufficient to fund the st… https://t.co/SrlqYd9iBv
March 19th 2020, 4:03pm
BioRunUp @BioRunUp
$LXRX PROVIDES AN UPDATE ON THE SOTAGLIFLOZIN TYPE 2 DIABETES PROGRAM close out the studies early... a near-term… https://t.co/Uo9QQjFuFK
March 19th 2020, 4:03pm
odibro @odibro
$LXRX UPDATE ON THE SOTAGLIFLOZIN TYPE 2 DIABETES PROGRAM. Long-Term Outcomes Studies, SCORED and SOLOIST, to Clos… https://t.co/GxWtbBzfwP
March 19th 2020, 4:03pm
ZolmaxNews @ZolmaxNews
Lexicon Pharmaceuticals’ $LXRX Buy Rating Reaffirmed at Wedbush https://t.co/FKwUPE2255
March 19th 2020, 1:03am
TranscriptDaily @TranscriptDaily
Lexicon Pharmaceuticals’ $LXRX Buy Rating Reaffirmed at Wedbush https://t.co/tMKGyCypcT
March 19th 2020, 1:03am

DrugPatentWatch - Make Better Decisions
Contact © thinkBiotech LLC 2004 - 2020. All rights reserved.